DARE

SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience, is scheduled to present at Stifel's 2026 Healthcare Conference happening November 10 – 12, 2026 in New York, New York.

Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%

View the video webcast here

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

Video webcast now available  here

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript